Verastem Oncology said new long-term follow-up data from the Phase 2 RAMP 201 trial of the avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer will be presented at the Society of Gynecologic Oncology 2026 Annual Meeting. The data are scheduled for an oral plenary presentation by Rachel Grisham on April 10, 2026. Verastem also plans a poster on an exposure-response analysis for the combination in low-grade serous ovarian cancer, presented by Yaofeng Cheng on April 12, 2026. RAMP 201 is a Phase 2, registration-directed trial that evaluated avutometinib alone and in combination with defactinib, with expansion phases using avutometinib 3.2 mg twice weekly and defactinib 200 mg twice daily. The company said the FDA approved the AVMAPKI FAKZYNJA co-pack on May 8, 2025, for adults with KRAS-mutated recurrent low-grade serous ovarian cancer who previously received systemic therapy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603171644BIZWIRE_USPR_____20260317_BW686920) on March 17, 2026, and is solely responsible for the information contained therein.
Comments